Sparbier, Christina E.
Gillespie, Andrea
Gomez, Juliana
Kumari, Nishi
Motazedian, Ali
Chan, Kah Lok http://orcid.org/0000-0002-9620-5558
Bell, Charles C. http://orcid.org/0000-0003-2194-8311
Gilan, Omer
Chan, Yih-Chih http://orcid.org/0000-0003-2177-5406
Popp, Sarah
Gough, Daniel J.
Eckersley-Maslin, Melanie A. http://orcid.org/0000-0002-0168-0373
Dawson, Sarah-Jane http://orcid.org/0000-0002-8276-0374
Lehner, Paul J. http://orcid.org/0000-0001-9383-1054
Sutherland, Kate D.
Ernst, Patricia http://orcid.org/0000-0001-7638-2939
McGeehan, Gerard M.
Lam, Enid Y. N. http://orcid.org/0000-0001-5843-7836
Burr, Marian L. http://orcid.org/0000-0002-8995-3398
Dawson, Mark A. http://orcid.org/0000-0002-5464-5029
Article History
Received: 30 September 2021
Accepted: 15 November 2022
First Online: 12 January 2023
Competing interests
: M.A.D. has been a member of advisory boards for GSK, CTX CRC, Storm Therapeutics, Celgene and Cambridge Epigenetix. The Dawson Laboratory is a recipient of grant funding through the emerging science fund administered through Pfizer. S.J.D. has been a member of advisory boards for Adela and Inivata. P.E. owns Amgen stocks (less than 5% value of the company) and has undertaken previous consulting for Servier (less than $10,000). G.M.M. is employed by Syndax Pharmaceuticals. The remaining authors declare no competing interests.